NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
USA - NYSE:NMR - US65535H2085 - ADR
7.56 USD
+0.07 (+0.93%)
7.56 USD
0 (0%)
Taking everything into account, NMR scores 3 out of 10 in our fundamental rating. NMR was compared to 237 industry peers in the Capital Markets industry. Both the profitability and financial health of NMR have multiple concerns. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NMR was profitable.
NMR had a negative operating cash flow in the past year.
In the past 5 years NMR has always been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
1.2 Ratios
NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 69.62% of its industry peers.
With a Return On Equity value of 9.82%, NMR perfoms like the industry average, outperforming 56.54% of the companies in the same industry.
The Return On Invested Capital of NMR (0.63%) is worse than 71.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.61%.
The last Return On Invested Capital (0.63%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROIC | 0.63% |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
1.3 Margins
Looking at the Profit Margin, with a value of 7.19%, NMR is doing worse than 64.13% of the companies in the same industry.
In the last couple of years the Profit Margin of NMR has declined.
NMR has a worse Operating Margin (9.96%) than 68.78% of its industry peers.
NMR's Operating Margin has declined in the last couple of years.
The Gross Margin of NMR (39.95%) is worse than 64.13% of its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% |
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
2. Health
2.1 Basic Checks
Compared to 1 year ago, NMR has less shares outstanding
NMR has less shares outstanding than it did 5 years ago.
NMR has a better debt/assets ratio than last year.
2.2 Solvency
NMR has an Altman-Z score of -0.27. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
NMR's Altman-Z score of -0.27 is on the low side compared to the rest of the industry. NMR is outperformed by 76.37% of its industry peers.
A Debt/Equity ratio of 10.44 is on the high side and indicates that NMR has dependencies on debt financing.
NMR has a worse Debt to Equity ratio (10.44) than 89.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.27 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.22 indicates that NMR may have some problems paying its short term obligations.
With a Current ratio value of 0.22, NMR is not doing good in the industry: 87.76% of the companies in the same industry are doing better.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NMR (0.22) is worse than 87.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 |
3. Growth
3.1 Past
NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.28%, which is quite impressive.
Measured over the past years, NMR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.96% on average per year.
Looking at the last year, NMR shows a small growth in Revenue. The Revenue has grown by 4.32% in the last year.
The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
3.2 Future
Based on estimates for the next years, NMR will show a small growth in Earnings Per Share. The EPS will grow by 0.23% on average per year.
The Revenue is expected to decrease by -6.34% on average over the next years.
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.31, the valuation of NMR can be described as very reasonable.
82.70% of the companies in the same industry are more expensive than NMR, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.41. NMR is valued rather cheaply when compared to this.
NMR is valuated reasonably with a Price/Forward Earnings ratio of 9.45.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 78.48% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NMR to the average of the S&P500 Index (22.88), we can say NMR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.31 | ||
| Fwd PE | 9.45 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 70.46% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.8 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.76
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 3.94%.
NMR's Dividend Yield is comparable with the industry average which is at 7.96.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.94% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 33.03% of its income as dividend. This is a sustainable payout ratio.
NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.03%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
7.56
+0.07 (+0.93%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.49%
Inst Owner Change4.93%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.18B
Analysts73.33
Price Target7.73 (2.25%)
Short Float %0.07%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.94% |
Yearly Dividend0.27
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.65%
PT rev (3m)7.94%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)177.61%
EPS NY rev (1m)2.05%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-18.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.31 | ||
| Fwd PE | 9.45 | ||
| P/S | 0.69 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.94 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 22.8 |
EPS(TTM)0.91
EY12.04%
EPS(NY)0.8
Fwd EY10.58%
FCF(TTM)-3.61
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS11.03
BVpS8.08
TBVpS7.91
PEG (NY)N/A
PEG (5Y)0.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | 9.82% | ||
| ROCE | 1.65% | ||
| ROIC | 0.63% | ||
| ROICexc | 0.69% | ||
| ROICexgc | 0.7% | ||
| OM | 9.96% | ||
| PM (TTM) | 7.19% | ||
| GM | 39.95% | ||
| FCFM | N/A |
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexcg growth 3Y16.87%
ROICexcg growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 67.92 | ||
| Cap/Depr | 1410.99% | ||
| Cap/Sales | 18.37% | ||
| Interest Coverage | 0.16 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -0.27 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.28%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%62.38%
EPS Next Y-2.18%
EPS Next 2Y-0.93%
EPS Next 3Y0.23%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%-4.36%
Revenue Next Year-21.32%
Revenue Next 2Y-10.98%
Revenue Next 3Y-6.34%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20149.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A